Schwarze-Zander, C., Steffens, B., Emmelkamp, J., Kuemmerle, T., Boesecke, C., Wasmuth, J. C., Strassburg, C. P., Faetkenheuer, G., Rockstroh, J. K. and Eis-Huebinger, A. M. (2016). How successful is influenza vaccination in HIV infected patients? Results from an influenza A(H1N1)pdm09 vaccine study. HIV AIDS Rev., 15 (3). S. 111 - 116. WROCLAW: ELSEVIER URBAN & PARTNER SP Z O O. ISSN 1732-2707

Full text not available from this repository.

Abstract

Aim: To determine immune response after single vaccination with AS03-adjuvanted pandemic H1N1 vaccine in HIV-infected patients. Background: Individuals living with human immunodeficiency virus (HIV) are at risk with influenza due to hyporesponsiveness to influenza vaccine and a higher probability for developing severe disease. Especially, immunogenicity and tolerability of adjuvanted influenza vaccines in a pandemic setting are not well characterized in HIV infected individuals. Methods: Immune response following vaccination with a single dose of influenza A(H1N1)pdm09 AS03-adjuvanted vaccine (H1N1pdm09 vaccine) containing 3.75 mu g hemagglutinin was evaluated in HIV infected individuals by hemagglutination inhibition assay. Tolerability was assessed by questionnaires. Results: Three hundred eighty-nine patients from two German HIV clinics were evaluated. Seroprotection was found in as much as 191/389 (49%) of patients before vaccination. Following vaccination with H1N1pdm09 vaccine seroprotection rate increased to 66% (257/389). Due to high pre-vaccination seroprotection rates seroconversion was only found in a total of 27/389 (7%) of HIV patients. There was no association of seroprotection/seroconversion and current CD4(+) T-cell count, HIV-RNA load in plasma, antiretroviral treatment or demographic factors such as gender, age and ethnicity. The vaccine was overall well tolerated. Conclusions: In this large cohort of HIV infected patients with high baseline H1N1 seroprotective titers only a moderate antibody response to a single vaccination with H1N1pdm09 AS03-adjuvanted vaccine was detected. Emerging influenza pandemics warrant usage of booster vaccinations in order to achieve higher immunogenicity to protect a vulnerable patient population such as HIV positive individuals against influenza. (C) 2016 Polish AIDS Research Society. Published by Elsevier Sp. zo.o. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Schwarze-Zander, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steffens, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Emmelkamp, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuemmerle, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boesecke, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wasmuth, J. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Strassburg, C. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Faetkenheuer, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rockstroh, J. K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eis-Huebinger, A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-288441
DOI: 10.1016/j.hivar.2016.04.002
Journal or Publication Title: HIV AIDS Rev.
Volume: 15
Number: 3
Page Range: S. 111 - 116
Date: 2016
Publisher: ELSEVIER URBAN & PARTNER SP Z O O
Place of Publication: WROCLAW
ISSN: 1732-2707
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HIV-1-INFECTED PATIENTS; H1N1 INFLUENZA; A H1N1; HUMORAL RESPONSE; IMMUNE-RESPONSE; SPLIT VIRION; IMMUNOGENICITY; INDIVIDUALS; ADULTS; METAANALYSISMultiple languages
Infectious DiseasesMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/28844

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item